This targeted approach can help restore more optimal growth hormone levels, potentially alleviating the symptoms associated with GHD
Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously
This is often called the trough. Use this time to focus on high-protein meals and practicing the healthy eating habits you are developing during the program
Why GLP-1 Medications Can Affect Collagen GLP-1s work by reducing appetite and slowing digestion, which helps you eat fewer calories
This means there was no systematic way to monitor how much Tylenol a pregnant woman consumed
Do I need lab work before starting GLP-1 injections Yes
